Amycretin

Fat LossInvestigational GLP-1 + amylin unimolecular agonistEmerging

Novo Nordisk unimolecular GLP-1 and amylin receptor agonist in oral and subcutaneous forms, advancing to Phase 3. Not FDA-approved. Distinct from CagriSema.

Calculate Dose

For research use only.

Key Facts

CAS: —
Molecular Weight (MW): —
Half-life: —
Unit: mg
Administration Route: Oral or Subcutaneous
Frequency: Daily oral or weekly SC (formulation-dependent)
Last updated: 8/23/2026
Targets: GLP-1 receptorAmylin receptor

Overview

Novo Nordisk unimolecular GLP-1 and amylin receptor agonist in oral and subcutaneous forms, advancing to Phase 3. Not FDA-approved. Distinct from CagriSema.

Protocol

Dosage Range: Oral and SC titration in early-phase / Phase 3 programs
Frequency: Daily oral or weekly SC (formulation-dependent)
Cycle: —
Administration Route: Oral or Subcutaneous
Reconstitution Guide: —

Science

Mechanism of Action

Single peptide activates GLP-1 and amylin receptors. 2025 Lancet early-phase papers reported substantial weight loss with injectable and oral formulations.